Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation

Boris Strasberg, Alex Sagie, Eldad Rechavia, Amos Katz, Ilya A. Ovsyscher, Samuel Sclarovsky, Jacob Agmon

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Three patients presented to the emergency room with atrial fibrillation and fast ventricular response with wide preexcited QRS complexes (Wolff-Parkinson-White syndrome). All three patients received intravenous verapamil (5-10mg). The first patient developed ventricular fibrillation requiring several defibrillations; the second patient developed severe hemodynamic deterioration requiring urgent cardioversion; in the third patient a marked increment in the ventricular response was noted, however, there was no hemodynamic impairment. Verapamil may cause detrimental results when given to patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Its administration should therefore be considered as an absolute contraindication in these patients.

Original languageEnglish
Pages (from-to)801-806
Number of pages6
JournalCardiovascular Drugs and Therapy
Issue number6
StatePublished - 1 Jan 1989
Externally publishedYes


  • Wolff-Parkinson-White
  • arrhythmias
  • verapamil

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation'. Together they form a unique fingerprint.

Cite this